Minireviews
Copyright ©The Author(s) 2015.
World J Hepatol. May 28, 2015; 7(9): 1272-1281
Published online May 28, 2015. doi: 10.4254/wjh.v7.i9.1272
Table 1 Novel anti-hepatitis B virus compounds in development
Therapeutic agentsMechanismManufacturerStatus
Viral entry inhibitors
Myrcludex BEntry inhibitionMyr_GmbH, GermanyPhase IIA, Russia
cccDNA Transcription inhibitors
CC-0975, CC-0346 (DSS)Induces deproteinization of rcDNAPreclinical
LTβRInduces cccDNA cytidine deaminationPreclinical
Small moleculescccDNA transcription inhibitorPreclinical
DNA editing technology
ZFNscccDNA inactivationPreclinical
TALENscccDNA inactivationPreclinical
RNAi gene silencer
ARC 520RNAi gene silencerArrowhead Research Pasadena, CAPhase IIA
New nucleoside analogues
Besifovir (LB80380)Inhibits viral DNA polymeraseLG Life Sciences, South KoreaPhase II
MIV-210Inhibits viral DNA polymeraseMedivir/Daewoong, South KoreaPhase II
Tenofovir alafenamide (GS-7340)Prodrug of tenofovirGilead Foster City, CAPhase III
Interruption of HBV capsid assembly
Heteroaryldihydropyrimidine (Bay 41-4109)Inhibits viral nucleocapsidAiCuris, GermanyPhaseI
Heteroaryldihydropyrimidine (HAP12)Inhibits capsid assemblyPreclinical
NVR-1221Capsid inhibitorNovira Therapeutics, Doylestown, PAPhase IA
HBsAg release inhibitor
REP 9ACHBsAg release inhibitorREPLICor Inc. Montreal, QuebecPhase I
HBsAg-3 shRNAHBsAg expression inhibitorPreclinical
Immunomodulator
GS-9620TLR-7 agonistGilead Foster City, United StatesPhase I
CYT 107 (interleukin-7)ImmunomodulatorCytheris, Paris, FrancePhase I/IIA
Therapeutic vaccination
GS-4774HBV X, surface and core antigensGilead Sciences with Globe Immune Louisville, COPhase II
DV601HBV surface and core antigensDynavax, Berkeley, CAPhase IB
NASVACHBV surface and core antigensCIGB, CubaPhase I
HBV core Ag vaccineT-cell mediated therapeutic vaccineEmergent Europe, United KingdomPhase I